Natera (NTRA) Stock Forecast & Price Target

Natera is a frontrunner in the genetic testing industry with a strong financial position, a BUY rating, and a raised price target. Their expected growth in Signatera volume and Medicare coverage, along with a focus on expanding into new markets and developing new tests, will lead to an increase in revenue and profit. With a first-mover advantage, Natera has the potential for long-term success and is actively working towards changing disease management and increasing gross margins through insurance negotiations.

Natera is relying heavily on the growth and success of its Signatera molecular residual disease test, which has seen strong demand for its robust volume growth and high ASPs, leading to record sequential quarters and a path to reach $2,000 per test. However, the company's attachment to the entire immunotherapy class and reliance on a single therapy study may limit future growth potential, and a failure to meet investor expectations on Signatera's growth could negatively impact stock performance.